Gastric cancer (GC) is one of the most common cancers in the northern region of Brazil, the second most common in men and the fifth most common in women, according to the National Cancer Institute (INCA). In addition, its symptoms are non-specific in the early stages of the disease, which contributes to late diagnosis, poor prognosis, and resistance to conventional chemotherapy. In this context, Natural Products (NPs) are a promising pharmacological alternative, due to the chemical structural diversity of their bioactives. Among the NPs, essential oils have crucial biochemical advantages for the chemical remodeling of compounds, increasing efficiency and broadening therapeutic proposals. Specifically, the oils of the Piperaceae family, which are sources of phytochemicals, stand out for their high antineoplastic potential. The aim of this study was to evaluate the antiproliferative action of OEPV oil on primary (ACP03) and metastatic (AGP01) gastric cancer cell lines. The method used the succinimidyl ester of carboxyfluorescein diacetate (CFSE), whose intensity changes according to cell duplication, which makes it a parameter for identifying cell generations according to the variation in fluorescence intensity. To carry out the work, 70³ cells/well were seeded with the CFSE incorporation, with the exception of the white group, and incubated for 24 hours in an oven at 37ºC with 5% CO2. Subsequently, treatment was carried out with OEPV at concentrations of 6?g and 12?g, which was kept in the incubator for 72 hours. Finally, cytometry analysis was performed after harvesting the cells and washing them with PBS 1x followed by resuspension in PBS 1X. In addition, for the calibration of the equipment (FacsVerse BD®), groups with minimum and maximum fluorescence were used, i.e., unlabeled groups and groups labeled immediately at the time of analysis, respectively. The results showed that there was a decrease in proliferation in both strains after treatment with OEPV oil. The AGP01 strain showed a significance of p<0.01 at concentrations of 6µg and 12µg. For ACP03, the significance was p<0.05 at both concentrations. Thus, the data from this study point to the oil's antiproliferative activity as a potential substance for use in anticancer therapies. This study achieved its objective in terms of quantifying and evaluating the ability of phytochemicals to reduce cell division in GC cells.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
